AZN vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jan 30, 2026

AZN

55.4
AI Score
VS
GSK Wins

GSK

65.2
AI Score

Investment Advisor Scores

AZN

Jan 30, 2026
55score
Recommendation
HOLD

GSK

Jan 30, 2026
65score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric AZN GSK Winner
Forward P/E 18.797 9.6432 GSK
PEG Ratio 1.1114 0.4287 GSK
Revenue Growth 12.0% 6.7% AZN
Earnings Growth 78.0% 23.2% AZN
Tradestie Score 55.4/100 65.2/100 GSK
Profit Margin 16.2% 17.1% GSK
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD BUY GSK

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.